Entering pharmacovigilance writing
Pharmacovigilance writing, or safety writing, is the medical-writing specialism that prepares a medicine's safety documents, and it arose when European regulation made those documents complex enough to need a professional writer. A writer entering it meets its relation to clinical writing, what the role asks and how a company organises the work, how long the specialism takes to learn and where the training is, the demand for writers and the specialism's standing, and the routes in and the ordinary working day.
How the specialism arose
Pharmacovigilance as a science began more than 170 years ago, but one safety writer, writing in 2026, dates the recognition of safety writing as a medical writing area to around 2010. In that writer's account, the reason is that requirements, processes and document complexity evolved over time, with significant strengthening and major changes, for instance in the early 1960s after the thalidomide tragedy, and in the late 1990s and early 2000s, when the post-marketing surveillance system began to aim to plan proactively how to prevent and minimise a product's risks. In parallel, document management grew more complex and the need for technical support increased, with a new submission format for regulatory documents, the electronic Common Technical Document, which the ICH approved in 2008. In Europe the EMA worked on new pharmacovigilance legislation and published drafts of the related good pharmacovigilance practice guidelines for public consultation, and between 2010 and 2012 it became clear that implementing the new legislation and guidance, the pharma package, would have a major impact on processes and documents. Risk management plans and periodic safety update reports gained complexity in their formal and content requirements, and their lifecycle management grew more complex with assessment by the Pharmacovigilance Risk Assessment Committee and more post-submission activities. The greater complexity of pharmacovigilance requirements and key documents created a need for a new professional role to support safety physicians and their activities, the safety medical writer, who applies a professional medical writer's skills to the field and has expertise in pharmacovigilance document guidance, requirements and related processes.
Pharmacovigilance was once not really perceived as a writing task: the guidance was mainly ICH E2E and Volume 9A, writers and, mainly, pharmacovigilance physicians wrote risk management plans, periodic safety update reports and other aggregate safety reports from it, and in one practitioner's experience pharmacovigilance documents were not considered a task for medical writers until 2012. In that practitioner's account, pharmacovigilance writing was officially born in 2012, when the European pharma package, and its good pharmacovigilance practice guidance in particular, were issued. A 2015 account names the same framework, the good pharmacovigilance practices the EMA introduced in 2012 under the new pharmacovigilance legislation, as what gave a new medical writing role, the pharmacovigilance medical writer, the opportunity to develop. In that account, drug safety professionals had normally prepared risk management plans and periodic safety update reports before the pharma package, and under the new legislation both became complex, multidisciplinary documents with a new modular format, needing a large amount of data and analyses across the pre- and post-authorisation phases, which made them a task for highly specialised pharmacovigilance medical writers.
In 2012, the earlier practitioner recalls, making people aware of the role of medical writing could have seemed like promoting writers' professional role, but the complexity that the good pharmacovigilance practice guidance introduced to the documents really needs a professional writer. Such a writer is used to managing a large number of documents, coordinates the preparation of complex documents and a team of authors with different responsibilities and competences, and works to very tight timelines, which are project-management skills writers do have. In the same practitioner's view, pharmacovigilance documents, like other regulatory and clinical documents, are a task for writers, and the complexity of these highly structured, highly regulated documents makes it good to have professional writers write them or coordinate their preparation.
From 2012, in that practitioner's account, there were many initiatives to make pharmacovigilance employees and others aware of a new chance for medical writers to step into the pharmacovigilance field. EMWA expanded the number of workshops it offered at its conferences: where the practitioner recalls a workshop on periodic safety update reports and development safety update reports, from 2012–13 several workshops also addressed the risk management plan. EMWA's journal carried a number of articles on pharmacovigilance as a general topic, on the new guidance and on specific documents. Many workshops also ran outside the association, and across them the practitioner noticed an increasing awareness of the professional role of medical writers in pharmacovigilance. EMWA then held a spring symposium on risk-benefit evaluation in Dublin in May 2015, which presented benefit-risk under the new pharma package guidance in terms of the role of professional medical writers and of writing appropriately, in a highly regulated way, for the aim of patient safety. The practitioner counts as another milestone in raising awareness of writers' role the 2016 DIA EuroMeeting in Hamburg, which had, the practitioner thinks for the first time, a proper medical writing session, with a subsession on risk-benefit and pharmacovigilance writing.
How it relates to clinical writing
Medical writing has not traditionally included pharmacovigilance writing, although there are many similarities, and one practitioner held at a 2018 AMWA conference session that pharmacovigilance writing is medical writing. Pharmacovigilance activities are documented across a drug's lifecycle, including after approval. The two kinds of writing track many of the same data, among them adverse events, drug usage, patient information, authorised indications and general safety information, and in both the writer analyses and summarises the data. They differ in their data: clinical development covers the data before a drug's approval, in a highly controlled setting, whereas pharmacovigilance also covers the data after authorisation; much more patient information is available for pharmacovigilance, and because these data are not gathered only in a clinical setting, missing data are normal. Pharmacovigilance documents may also reach a broader audience, externally the US Food and Drug Administration, patients and ethics committees, and internally outcomes research, clinical development and medical affairs.
A pharmacovigilance writer is also a medical writer and needs the typical medical writing skills: presenting data with high quality and high clarity, working against timelines, coordinating processes and high numbers of documents, ensuring compliance and consistency across the modules and documents within a dossier, and using proper language and style. In a poll at a 2019 webinar, 63% of the attendees who voted said the writing skills needed in pharmacovigilance and in clinical writing differ.
What the role asks of a writer
In the account of the practitioner who gave that webinar, a pharmacovigilance writer has to be a document expert, in format and in content. The writer also needs good knowledge of the regulatory requirements for the pharmacovigilance documents to be prepared, and some knowledge of regulatory procedures to help guide the team's discussions and decisions, such as the best format for a risk management plan or the best point in time to prepare RMPs and PSURs. The writer needs a good understanding of pharmacovigilance and risk-management activities across a product's lifecycle to define the safety concerns, the important risks in particular, and to categorise and recategorise them, because they change during the lifecycle: an important risk may no longer be important after a certain time or when risk minimisation measures are very well applied. And the writer understands the principles of risk management, which needs a very good background in pharmacovigilance.
Asked in the same webinar what the role of a professional medical writer preparing pharmacovigilance documents is, 90% of the attendees who voted chose all of document expertise, expertise in the guidance and requirements, and knowledge of regulatory procedures; 8% chose the guidance-and-procedures option and 2% document content and format alone. The practitioner's own answer was that in pharmacovigilance there is basically no black and white and no correct and wrong, so the answer to such questions is not so clear.
The 2015 account's ideal profile of a pharmacovigilance medical writer includes pharmacovigilance expertise; extensive knowledge of the formal requirements and guidelines; document, format and content expertise; and writing, communication and project management skills, and the writer often needs to look beyond preparing a single document to further regulatory aspects of document planning and assessment. In that account, a multidisciplinary pharmacovigilance document needs a skilled writer who ensures clear data presentation, effective medical communication and consistency of content and style across modules, and the writer plays a critical role in managing a high number of document files and versions and in ensuring that all contributions are provided and reviewed in time. The writer must have sound knowledge of the guidelines and should ensure that all contributions comply with the good pharmacovigilance practice requirements, and must also ensure that information in other submission documents, such as the clinical summaries, is in line with the data presented in a risk management plan. With that expertise and knowledge of the guidance and requirements, the writer adds value to planning the most appropriate document format and the level of detail of the data presentation, to discussions of risks and their categorisation as safety concerns, and to the strategic planning of how different but related documents are submitted. The same account gives the writer a key position in the context the pharma package created, leading the document creation process and providing oversight and guidance to the multidisciplinary authoring team.
A new pharmacovigilance writer should be familiar with the product, the disease and the events in focus, and should become familiar with the current guidance on the product, which changes frequently and comes from many sources. The practitioner who held that pharmacovigilance writing is medical writing described the career as one in which the writer must keep to tight timelines, accept that some data are missing, analyse and offer opinions to the team, and know the expected content of each document.
Pharmacovigilance document preparation is a global, cross-functional effort in which the writer leads and oversees the whole document development process: drafting the content, integrating the input of the functions and stakeholders involved, bringing in-depth knowledge of the guidelines and of the required format and content, and managing review and comment resolution. The submission strategy and document requirements can vary with factors such as the product, its indication and its authorisation pathway, and the end goal is always a high-quality document meeting the requirements for electronic submission to authorities around the world. The writer translates complex safety data into clear, scientifically accurate and compliant documents for authorities, healthcare professionals and the public, synthesising data from sources such as spontaneous adverse event reports, clinical study results, post-authorisation safety studies and literature review into structured safety reports, and ensuring that the documents adhere to international guidelines. The writer must maintain consistent medical terminology, apply standardised templates and present balanced benefit-risk evaluations aligned with current regulatory expectations, and works closely with pharmacovigilance, regulatory affairs, biostatistics and clinical teams to resolve data discrepancies, clarify interpretations and ensure accuracy under often tight submission timelines. The role needs scientific literacy and communication expertise together, because the writer has to convey evolving safety information to stakeholders precisely, transparently and in line with legal obligations.
How safety writing is organised in a company
Which documents safety writers prepare may vary with the structure and responsibilities within a company. In one pharmaceutical company, described in 2026, safety writing makes no distinction between the clinical and the post-marketing setting: one safety writing group prepares the regulatory pharmacovigilance documents across a product's lifecycle, the DSUR in clinical development, the RMP at the application for first marketing authorisation, RMP updates and the PSUR in the post-marketing phase, and the addendum to the clinical overview at the application for renewal, and the safety writer ensures continuity and oversight of the writing before and after submission. In that group it is not meaningful, for resources and demand, to allocate a writer to particular documents, therapeutic areas or products, but the tasks are structured to ensure continuity as far as possible. For a product with complex RMPs and PSURs and many health authority requests from assessment reports, the same writer may be appointed over several years, and the principal safety writers are responsible for the RMPs submitted for a first marketing authorisation and may then take over the PSURs for the newly authorised product over its first few years. The group generally works across therapeutic areas but tries to offer continuity, especially for projects such as first submissions for marketing authorisation in oncology, where specialising in a therapeutic area may be meaningful.
Who writes patient safety narratives may depend on how they are defined and on the company's structure: safety data managers usually write the narratives for individual case safety reports, and narratives in clinical trial settings are likely the clinical medical writers' responsibility. Safety narratives may also be needed before and after authorisation to support, for instance, a DSUR or PSUR, safety reviews or signal assessment reports, and these are likely prepared by the safety writers or the product safety physicians. In the same company the clinical medical writing group prepares clinical submission documents focusing on safety, such as the summary of clinical safety. Its safety writing group does not prepare patient safety narratives, except as additional support for the safety physicians.
Regulatory safety writing and public-facing safety communication are very different writing areas, because their audiences differ: safety writing needs technical writing skills and prepares regulatory submission documents read by scientists at the authorities, while public-facing safety communications, which may be regulatory or medical communication documents, need skills in lay language and communication with the public. Requirements for pharmacovigilance regulatory documents differ across countries and regions, and depending on a company's structure the documents may be prepared globally, then translated into local languages and adapted as needed to local requirements, or locally, in the local language and to local requirements; both need professionals with local pharmacovigilance expertise and medical writing skills.
Learning the specialism
For someone new to medical writing, becoming a pharmacovigilance writer may take about as long as becoming a clinical writer, in one practitioner's 2019 estimate: it could take up to two years to be fit enough to work independently, which is no longer than for clinical writers. The only difference is that the writer has to specialise in pharmacovigilance, learning its regulations and guidance in addition to the documents' format and requirements.
In 2019 EMWA offered workshops related to the topics of pharmacovigilance writing, where a writer can get training. For someone completely new to pharmacovigilance, background workshops teach how to evaluate and understand the adverse effects of a medicine, how to present data such as adverse events, concomitant medications and laboratory data, and how to understand measures of risk. For someone new to the documents, an introductory workshop covers the DSUR, the RMP and the PSUR together, and separate workshops are dedicated to each of them. Workshops with advanced content cover the risk management plan and the general post-submission tasks in pharmacovigilance writing for PSURs and RMPs. Beside the specialism, EMWA offers many workshops to develop writing skills: a couple of epidemiology courses for medical communicators could be good for preparing risk management plans, workshops on managing a writing project and on time management teach project-management skills, and others cover statistics, presenting data in tables and graphs, and writing skills. The practitioner who gave the 2019 webinar encouraged writers interested in pharmacovigilance writing to join EMWA's pharmacovigilance courses or those of its expert seminar series.
Demand for writers and the specialism's standing
In 2018 a member of EMWA's pharmacovigilance special interest group, speaking for the group, described a chronic need for experienced medical writers in the area and encouraged writers who had never considered working in it to look into it. The same speaker held that the industry was crying out for more writers experienced in pharmacovigilance, that the requirements were only increasing, and that the area, a niche at that time, would become more and more mainstream.
The owner of a medical writing company told a biochemistry graduate with ten years in the pharmaceutical industry, mostly in pharmacovigilance, that a sideways move from pharmacovigilance into medical writing is highly feasible, and that someone with pharmacovigilance experience would be of great interest to the company, because it was being asked more and more for PSURs and DSURs and did not really know how to write them.
The editors of a 2025 journal issue devoted to safety writing hold that safety writing often stands in the shadow of regulatory writing, its more popular cousin, because aspiring writers understandably focus on regulatory writing, for which demand is stronger than ever with the clinical trial industry's sustained expansion, and yet safety writing never neglects its duty to assure public safety from early development through well-established use. In their view, over the decade since 2015 complex global regulation and evolving technology have only intensified the importance of safety writing. They also hold that the medical writer, standing at the intersection of data and public disclosure, plays a vital part in ensuring that the echoes of catastrophic events remain confined to the history books. An author in the same issue holds that as regulatory expectations continue to evolve and global harmonisation increases, the need for skilled medical writers with specialised pharmacovigilance expertise becomes more critical than ever. The same author holds that greater awareness of the field among healthcare professionals and researchers can foster greater collaboration and improve the overall quality of pharmacovigilance activities.
Thirteen years after the pharma package, the safety writer writing in 2026 calls safety writing an established working area but still a highly specialised niche within medical writing, with guidance and writing practice constantly evolving to reflect experience, a changing regulatory environment and growing engagement with healthcare professionals and patients. That writer finds the profession still less known than other medical writing areas. When the writer describes the profession in plain words, people usually ask whether a safety writer writes the side-effects section of the patient information leaflet, and the writer then explains side effect reporting and how it helps improve patients' safety, and that the work leads to listing side effects, warnings or contraindications in the leaflet.
In the same writer's experience, both freelance and employed, many safety writing projects can be effectively outsourced in whole or in part; meetings are held virtually across global teams, and technical access to a company's document management system and SharePoint platforms can be easily granted. The more experienced the freelance safety writer, the better the chance of contracts in the field. Preparing complex submission documents, coordinating and preparing responses to regulatory authorities, and even the technical management of documents can be challenging from outside a company. Pharmacovigilance requirements have also been strengthened in other fields, and new regulations and impactful guidance have made the documents they require more complex, and new opportunities have arisen for safety writers, for instance in medical devices. Within human pharmacovigilance, the working environment is being reshaped to gather real-world data and apply new technologies, automation and artificial intelligence tools that aim to speed up processes, save resources, ease document preparation and enhance quality, though the writer holds that preparing safety documents that support decisions with a high impact on patient safety cannot exclude human beings. The role can be complemented with pharmacovigilance expertise in some of the processes behind the documents, such as signal management, case evaluation and management, and literature review. The writer considers safety writing still an exciting opportunity for medical writers who would like to apply their skills to the pharmacovigilance field and acquire expertise in it. In that writer's view, the need for skilled professionals increases with the complexity of regulatory requirements and documents, and medical writers can fill the gaps by applying their skills and being open to change, which is good news for aspiring medical writers and for those considering a move to another medical writing field.
Routes in
One route runs from clinical-development writing into pharmacovigilance writing: one writer wrote publications for biomedical journals in academia from the late 1990s, worked at a university until 2002, then moved into the pharmaceutical industry as a medical writer in clinical development, working on several submissions and writing clinical trial reports in the US and in Germany, and joined a company in 2009 where, by 2020, he headed global pharmacovigilance writing, leading a group of writers who write DSURs, PBRERs, RMPs and many other documents for the company globally.
Another route began just by chance, for the safety writer writing in 2026. After almost ten years in basic and applied research, a doctorate and a postdoctoral fellowship included, she wanted a profession whose output was proportionate to the effort, heard the term medical writing from a friend, and applied for a medical writing position with no previous training or experience, obtaining an entry-level position at a contract research organisation that specialised in pharmacovigilance. For the first year she heard not a word about medical writing: she received intensive training in pharmacovigilance and gained experience in triage of reported adverse events and case creation, data entry of individual case safety reports, preparation of narratives, safety literature review and elements of medical evaluation, and soon led a group dedicated to safety literature review. A colleague told her about EMWA and the learning opportunities of its conference workshops, they joined a conference and began earning credits in EMWA's professional development programme, and at the same time she was assigned her first medical writing tasks. The company then extended its pharmacovigilance services to preparing PSURs and RMPs for clients, at a time when the role of the safety writer was yet to be born, and when the EMA announced the pharma package a few months later, she trained more colleagues in preparation for it, set up a safety writing group, was responsible for document planning and coordination and reviewed drafts before they went to clients, becoming over those two years one of the first and very few specialised safety writers. Freelance safety writing and pharmacovigilance document training for small, mid-sized and large pharmaceutical companies followed, then a permanent post as senior safety writer, where she learned the tasks that are often not outsourced: initial RMPs for first marketing authorisation applications, post-submission writing for health authority requests, and strategic document planning. Through volunteering at EMWA, where she co-organised conference events at the interface between safety writing and writing for the public, she came to a shadowing programme in her company on preparing regulatory summaries of clinical trials for the public. Her daily tasks in pharmacovigilance writing did not change after the programme, but her understanding of them did. A few years before 2026 her company renamed its Pharmacovigilance Writing group Patient Safety Writing, on the principle that safety writing is not just writing about patient safety but writing to keep patients safe.
The practitioner who held at the 2018 session that pharmacovigilance writing is medical writing also said that the search term medical writer was generally not used to describe pharmacovigilance careers. The search terms suggested for a pharmacovigilance job were pharmacovigilance scientist, analyst, author, writer, manager or specialist; safety scientist, specialist or writer; periodic report scientist, analyst, manager or officer; and associate, manager or director of pharmacovigilance.
The ordinary working day
A medical writer in drug safety at a small company, interviewed in 2008 about two years into the job, could not conceive of a typical day: the work seems to alternate between weeks with so little activity that a writer runs out of ways to fill the time and weeks of intense flurries. The work comes in waves because reporting requirements set the dates and deadlines and a writer is usually responsible for several trials at once. A hypothetical day starts by checking email for new adverse event reports; a new event is entered into the safety database and a sponsor assessment form sent off; then come whatever documents need work, which the writer lists as annual safety update reports, medical monitoring plans and dozens of safety narratives; the afternoon probably brings a meeting that keeps the writer abreast of the trials so that any impending reports are known; and the aim is to have completed something by the end of the day. The writer generally works alone, and can usually walk a few feet to the manager's office for clarification.
In the same writer's account, the most rewarding part of the work is that it benefits patients by helping to ensure that a drug is safe, and that its documents are submitted to regulatory authorities around the world. The most challenging part is constant learning, adapting to new tasks by building on what has gone before, made harder by the need to multitask: several reports from several studies at once, all of which have to be kept straight.